Mufg Securities Americas Inc. bought a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,589 shares of the company's stock, valued at approximately $582,000.
A number of other hedge funds have also recently modified their holdings of the company. Miracle Mile Advisors LLC purchased a new stake in Cencora in the fourth quarter worth $273,000. Signal Advisors Wealth LLC boosted its position in Cencora by 19.5% during the 4th quarter. Signal Advisors Wealth LLC now owns 1,831 shares of the company's stock valued at $411,000 after acquiring an additional 299 shares in the last quarter. Oak Thistle LLC purchased a new position in shares of Cencora during the 4th quarter worth approximately $455,000. Fifth Third Wealth Advisors LLC raised its position in shares of Cencora by 11.8% in the 4th quarter. Fifth Third Wealth Advisors LLC now owns 1,958 shares of the company's stock worth $440,000 after acquiring an additional 206 shares in the last quarter. Finally, Kathmere Capital Management LLC lifted its stake in shares of Cencora by 14.6% in the 4th quarter. Kathmere Capital Management LLC now owns 2,091 shares of the company's stock valued at $470,000 after purchasing an additional 266 shares during the period. Hedge funds and other institutional investors own 97.52% of the company's stock.
Insider Buying and Selling at Cencora
In other news, CEO Robert P. Mauch sold 4,969 shares of the company's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the sale, the chief executive officer now directly owns 47,582 shares in the company, valued at $13,766,900.06. This represents a 9.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the firm's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the transaction, the executive vice president now directly owns 14,665 shares in the company, valued at $3,934,326.20. This trade represents a 21.96% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,223 shares of company stock valued at $13,580,967. 10.80% of the stock is owned by company insiders.
Cencora Stock Up 0.7%
Shares of Cencora stock traded up $2.15 on Monday, reaching $292.37. The company's stock had a trading volume of 1,553,490 shares, compared to its average volume of 1,544,787. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $309.35. The firm's fifty day simple moving average is $279.87 and its two-hundred day simple moving average is $255.76. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The company has a market capitalization of $56.70 billion, a price-to-earnings ratio of 41.59, a P/E/G ratio of 1.31 and a beta of 0.60.
Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The firm had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. During the same period in the previous year, the company earned $3.80 earnings per share. The firm's quarterly revenue was up 10.3% on a year-over-year basis. Equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.
Cencora Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Investors of record on Friday, May 16th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date of this dividend is Friday, May 16th. Cencora's dividend payout ratio (DPR) is presently 25.52%.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on COR shares. Evercore ISI increased their price objective on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Citigroup lifted their price target on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Robert W. Baird raised their target price on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. JPMorgan Chase & Co. lifted their target price on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Finally, Bank of America upped their price target on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $301.18.
Read Our Latest Report on COR
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Further Reading
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
